BRCA1 and neoplasm: So, according to this combined model, it is sufficient to have at least one of the two markers at higher levels than the relative threshold in order to be classified as the tumor resistant to olaparib; on the contrary, when both RAD51 and BRCA1 foci are expressed at lower levels than their relative cut-offs, the tumors are likely to be sensitive to the treatment.